BMS — Deal History & Benchmarks
Market Analysis
BMS has been involved in 19 transactions totaling $243.2B across Oncology, Neurology & CNS, Hematology, Cardiovascular, Dermatology, Gastroenterology, Immunology & Autoimmune. As both a licensor and licensee, they have demonstrated an active acquisition strategy.
Key transactions include Celgene ($74B, 2019), Karuna Therapeutics ($14B, 2024), MyoKardia ($13.1B, 2022).
Their deal activity is concentrated in Oncology (42%) with Small Molecule and CAR-T assets representing their most common deal types.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How many deals has BMS done?
What is BMS's typical deal structure?
What therapeutic areas does BMS focus on?
How has BMS's deal activity trended over time?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.